Colorectal cancer · curated MDI catalog

Molecular tests for colorectal cancer

Colorectal-cancer molecular tests can address very different questions, from screening before diagnosis to treatment profiling and recurrence monitoring. MDI keeps those purposes separate.

26 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • Cancerguard — Multi-cancer early detection laboratory-developed test for adults 50–84; breast/prostate screening and precancer detection are outside the documented current use.
  • CancerNext — Guideline-based germline hereditary cancer panel.
  • CancerNext-Expanded — Germline hereditary-cancer panel; current vendor page reports 78 genes while recent official 77-gene materials require explicit version separation.
  • Cologuard — Stool-based colorectal cancer screening test for average-risk adults.
  • Cologuard Plus — Prescription multitarget stool-based colorectal cancer screening test for average-risk adults age 45 years or older.
  • ColoHealth — Blood-based methylated SEPT9 colorectal cancer testing family; current ColoHealth Direct LDT and historical FDA device lineage are modeled separately.
  • ColoSense — FDA-approved qualitative stool RNA and occult-hemoglobin colorectal cancer screening test for average-risk adults age 45 years or older.
  • EPISEEK — Blood-based multi-cancer early detection LDT analyzing abnormal DNA methylation signals associated with more than 60 cancer types.
  • Galleri — Prescription-only multi-cancer early detection test.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Invitae Hereditary Colorectal Cancer Guidelines-based Panel — NGS germline panel for hereditary colorectal cancer predisposition.
  • Invitae Personalized Cancer Monitoring — Tumor-informed personalized ctDNA monitoring assay for solid tumors.
  • Labcorp Plasma Detect Genome MRD — Tumor-informed whole-genome sequencing ctDNA MRD test currently offered for stage III colon cancer baseline and monitoring.
  • LucenceINSIGHT — Prescription blood-based multi-cancer early detection family using ctDNA and viral DNA with machine-learning tissue localization.
  • MyRisk — Germline hereditary-cancer panel; current documented configuration contains 63 clinically recommended genes and must not inherit analytical metrics from historical 25-gene validation.
  • NeXT Personal Dx — Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
  • Oncodetect MRD — Tumor-informed ctDNA molecular residual disease test used across solid tumors; current commercial configuration tracks up to 200 tumor-specific variants.
  • OneTest for Cancer — Blood-based multi-cancer early detection LDT combining multiple serum tumor biomarkers with a machine-learning risk algorithm.
  • OverC Multi-Cancer Detection — Blood-based cfDNA methylation multi-cancer early detection test with six-cancer current product scope; jurisdiction-specific regulatory status.
  • Precise MRD — Tumor-informed whole-genome sequencing MRD assay tracking up to 1,000 patient-specific variants for treatment and recurrence monitoring.
  • Shield — Blood-based colorectal cancer screening test.
  • SimpleScreen CRC — FDA-approved blood-based colorectal cancer screening test for average-risk adults age 45 and older.
  • SPOT-MAS 10 — Blood-based multi-cancer screening test using cfDNA methylation and fragmentomic signals with machine learning.
  • Tempus xF+ — 523-gene plasma liquid-biopsy comprehensive genomic profiling assay for therapy selection and molecular profiling in advanced cancer.
  • Tempus xM — Tumor-naive liquid-only MRD assay combining methylation- and variant-based workflows for stage II-III colorectal cancer.
  • therascreen KRAS RGQ PCR Kit — FDA-approved real-time PCR KRAS companion diagnostic for colorectal cancer.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance